Last week, the United States' Health and Human Services (HHS) and Food and Drug Administration (FDA) held a press conference to announce the removal of the black box warnings on estrogen-based hormone therapy, recognizing its safety when used appropriately. Members of the SMSNA, particularly those in the Female Sexual Function Committee, played an active role in advocating for this update.
